KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $22.99 and traded as high as $26.96. KalVista Pharmaceuticals shares last traded at $26.9450, with a volume of 6,431,370 shares.
Analysts Set New Price Targets
Several research firms have commented on KALV. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Finally, Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.60.
Check Out Our Latest Stock Analysis on KALV
KalVista Pharmaceuticals Stock Performance
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. On average, research analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.
Insider Buying and Selling at KalVista Pharmaceuticals
In related news, insider Paul K. Audhya sold 2,686 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the transaction, the insider owned 142,547 shares in the company, valued at approximately $2,882,300.34. This represents a 1.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the transaction, the insider owned 5,129,340 shares in the company, valued at approximately $86,942,313. This trade represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 261,295 shares of company stock worth $4,764,294 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.
Hedge Funds Weigh In On KalVista Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after purchasing an additional 818 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares in the last quarter. Rhumbline Advisers lifted its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,458 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in KalVista Pharmaceuticals by 137.0% in the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares in the last quarter.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Stories
- Five stocks we like better than KalVista Pharmaceuticals
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
